Search Results

Valeritas Holdings, Inc. (OTCPK: VLRXQ) (“Valeritas” or the “Company”), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court for the District of Delaware (the “Court”) approved the sale of substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) (“Zealand”), a Denmark-based biotechnology company

Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.

Valeritas Holdings, Inc., a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced an agreement to sell substantially all of the business to Zealand Pharma A/S, a Denmark-based biotechnology company.

Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional positive data from the VERDICT study was presented at the American Diabetes Association’s 79th Scientific Sessions held in San Francisco, California.

ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the appointment of Kristine Peterson to its Board of Directors.